GlaxoSmithKline Pharmaceuticals Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 3 Aug 2026

Company page: GlaxoSmithKline Pharmaceuticals share price, financials & guidance record

GlaxoSmithKline Pharmaceuticals Limited reported a strong Q1 FY27 with sales growing 15% to INR 924 crores and PAT increasing 24% to INR 253 crores, driven by robust performance in its innovation portfolio and established general medicines. EBITDA margins expanded by 50 bps, reflecting efficient operations despite increased investment in new launches. The company continues to focus on relentless top-line growth, accelerating its pipeline, and simplification, with new products contributing significantly to overall revenue.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 16.5%, net profit up 15.6% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	1,011	949	974	805	980 −3%	1,041 +10%	995 +2%	938 +17%
Expenses	689	658	641	554	644	670	644	643
EBITDA	322	292	333	251	336 +4%	371 +27%	351 +5%	296 +18%
Margin	32%	31%	34%	31%	34%	36%	35%	31%
Other income	39	35	41	44	36	50	36	44
Interest	0	0	1	0	1	1	1	1
Depreciation	17	19	15	16	17	20	13	16
Profit before tax	344	308	359	279	354 +3%	400 +30%	373 +4%	322 +15%
Tax rate	27%	25%	27%	27%	27%	26%	26%	26%
Net profit	252	230	263	205	257 +2%	296 +29%	278 +6%	237 +16%
EPS	14.91	13.57	15.52	12.10	15.20	17.45	16.40	14.00

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls